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Abstract: Gammacoronavirus infectious bronchitis virus (IBV) causes an economically important 
respiratory disease of poultry. Protective immunity is associated with the major structural protein, 
spike (S) glycoprotein, which induces neutralising antibodies and defines the serotype. Cross-
protective immunity between serotypes is limited and can be difficult to predict. In this study, the 
ability of two recombinant IBV vaccine candidates, BeauR-M41(S) and BeauR-4/91(S), to induce 
cross-protection against a third serotype, QX, was assessed. Both rIBVs are genetically based on the 
Beaudette genome with only the S gene derived from either M41 or 4/91, two unrelated serotypes. 
The use of these rIBVs allowed for the assessment of the potential of M41 and 4/91 S glycoproteins 
to induce cross-protective immunity against a heterologous QX challenge. The impact of the order 
of vaccination was also assessed. Homologous primary and secondary vaccination with BeauR-
M41(S) or BeauR-4/91(S) resulted in a significant reduction of infectious QX load in the trachea at 
four days post-challenge, whereas heterologous primary and secondary vaccination with BeauR-
M41(S) and BeauR-4/91(S) reduced viral RNA load in the conjunctiva-associated lymphoid tissue 
(CALT). Both homologous and heterologous vaccination regimes reduced clinical signs and birds 
recovered more rapidly as compared with an unvaccinated/challenge control group. Despite both 
rIBV BeauR-M41(S) and BeauR-4/91(S) displaying limited replication in vivo, serum titres in these 
vaccinated groups were higher as compared with the unvaccinated/challenge control group. This 
suggests that vaccination with rIBV primed the birds for a boosted humoral response to 
heterologous QX challenge. Collectively, vaccination with the rIBV elicited limited protection 
against challenge, with failure to protect against tracheal ciliostasis, clinical manifestations, and viral 
replication. The use of a less attenuated recombinant vector that replicates throughout the 
respiratory tract could be required to elicit a stronger and prolonged protective immune response. 
Keywords: infectious bronchitis virus; coronavirus; reverse genetics; recombinant vaccine; spike 
glycoprotein; heterologous challenge; cross-protection 
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1. Introduction 
Infectious bronchitis virus (IBV) is a Gammacoronavirus with a positive sense single-stranded 
RNA genome, consisting of a large replicase gene encoding 15 non-structural proteins (nsps); the 
structural genes including spike (S), membrane (M), envelope (E) and nucleocapsid (N); and the 
accessory genes including 3a, 3b, 4b, 4c, 5a, and 5b [1]. IBV is the aetiological agent of infectious 
bronchitis (IB), which is a disease of domestic fowl that is of both welfare and economic importance 
to the global poultry industry. Infected chickens display clinical signs including snicking, rales, 
watery eyes, nasal discharge, and lethargy; they exhibit reduced weight gain and impaired egg laying 
in terms of both quantity and quality [2,3]. In addition, infected birds are susceptible to secondary 
bacterial infections as a result of tracheal ciliostasis and immunosuppression [4,5]. 
Several serotypes and genotypes of IBV co-circulate in poultry flocks. The viral serotype is 
determined by the major structural protein, spike (S), a type 1 glycoprotein consisting of two 
subunits; the globular S1 subunit that mediates receptor-binding and the stalk-like S2 subunit that 
facilitates virus-to-cell and cell-to-cell fusion [6,7]. The majority of neutralising antibodies are targeted 
towards the S1 subunit, as this contains the receptor-binding domain [8–10]. The S2 subunit is more 
highly conserved than the S1 and also contains immunogenic regions, playing a role in both the 
generation of a protective immune response [6,11,12] and determining host tropism [13,14]. Several 
studies, including those utilising recombinant IBV to express full or partial S glycoproteins, have 
demonstrated the capability of the S protein to induce a degree of a protective humoral immune 
response against homologous challenge [11,12,15–19] and heterologous challenge [16,20,21].  
The real challenge in the control of IBV, however, is that vaccination against one serotype often 
offers limited cross-protection against another serotype. There is often a poor relationship correlation 
between the level of protection afforded by a vaccine and the level of homology between S 
glycoproteins from challenge and vaccine strains [22]. Although the mechanisms behind cross-
protection still remain to be elucidated, cross-protection can be evident with unrelated vaccine and 
challenge strains [16,21–26]. The application of commercial vaccines of two serotypes, Ma5 and 4/91, 
against challenge with a third serotype, QX, indicated induction of protective immune response 
against QX, as the challenge virus was not re-isolated from the trachea [21]. This induction of cross-
protective immunity occurred, despite the fact that there was a low genetic relationship between the 
hypervariable region of the S1 subunit of Ma5 and QX (77.1%) and of that between 4/91 and QX (81%) 
[21]. Conversely, studies have demonstrated limited cross-protection between strains with high 
sequence homology [23,27,28]. Despite 95% sequence homology between the S glycoproteins of two 
viruses belonging to the Massachusetts serotype, vaccination with IBV Beaudette cannot confer 
protection against a M41-CK challenge [15]. Collectively, this suggests that a small number of virus 
neutralising epitopes play a disproportionate role in cross-protection, which can make it difficult to 
predict effective vaccine strategies [22].  
Effective vaccination against IBV is proving to be an increasing challenge due to the emergence 
of novel strains, such as QX, first isolated in China, in 1995 [29], and subsequently spread worldwide 
[30–32]. Whilst some strains of IBV have spread worldwide, others have emerged but remained 
limited to distinct geographical areas [33,34]. Commercial live IBV vaccines are generated through 
multiple passages of a pathogenic field isolate through embryonated hen’s eggs with the aim of 
generating a virus that is attenuated but still immunogenic [35,36]. However, attenuation by this 
method is unpredictable and results in different patterns of genomic variations [37]. Given the nature 
of this process, it is challenging to readily respond to emerging strains in a time appropriate manner. 
The development of reverse genetic systems for IBV [38–40] has opened the possibility of using 
recombinant IBVs (rIBVs) as vaccines that can be rationally designed and readily manufactured, 
removing the cumbersome trial and error prone method of attenuation by multiple passages through 
embryonated hens’ eggs [37]. In this study, we investigated the use of two rIBVs, BeauR-M41(S) and 
BeauR-4/91(S), genetically based on the Beaudette genome with only the S gene derived from a 
different strain, either M41 or 4/91. Both rIBVs have been shown previously to induce partial 
protection against homologous and heterologous challenge [15,16], but not against heterologous 
challenge with the QX strain. Here, birds received a primary vaccination of either BeauR-M41(S) or 
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BeauR-4/91(S), and then received a boost with a secondary vaccination of either BeauR-M41(S) or 
BeauR-4/91(S). The effects of the order in which both vaccines were given on the level of protection 
and the humoral responses were also investigated. Therefore, through these rIBVs we were able to 
assess the level of cross-protection induced by M41 and 4/91 S glycoprotein against a heterologous 
QX challenge.  
2. Materials and Methods  
2.1. Ethical Statement 
All animal experimental protocols were carried out in strict accordance with the UK Home 
Office guidelines and under license granted for experiments involving regulated procedures on 
animals protected under the UK Animals (Scientific Procedures) Act 1986. The experiments were 
performed in The Pirbright Institute Home Office licensed (X24684464) experimental animal house 
facilities and were approved by the animal welfare and ethical review committee under the terms of 
reference HO-ERP-01-1. 
2.2. Cells and Viruses  
Primary chicken kidney (CK) cells were prepared from kidneys extracted from two- to three-
week-old specific-pathogen-free (SPF) Rhode Island Red (RIR) chickens [41]. All cell cultures were 
maintained at 37 °C and 5% CO2. Primary tracheal organ cultures (TOCs) were prepared from 19-
day-old RIR SPF embryos [42]. Cultures were maintained at 37 °C, rotating at 7–8 revolutions per 
hour. Recombinant IBV Beau-R and vaccine viruses, rIBV BeauR-M41(S) and BeauR-4/91(S), have 
been described previously [15,16,38,43]. Both vaccine viruses contain the signal sequence, the 
ectodomain and the transmembrane domain from either M41-CK (GenBank accession number 
X04722) or 4/91(UK) (GenBank accession number JN192154). The cytoplasmic tail had been derived 
from the Beau-R backbone (GenBank accession number AJ311317) and was maintained to preserve 
interactions with Beaudette-derived viral proteins. The virulent challenge strain QX L1148 [31] 
(GenBank accession number KY933090) was a gift from Professor Richard Jones at the University of 
Liverpool. All viruses were propagated in 10-day-old SPF RIR embryonated hens’ eggs and BeauR-
M41(S) was titrated in triplicate in CK cells. As neither IBV QX nor rIBV BeauR-4/91(S) can replicate 
in cell culture [14,16], they were titrated in TOCs, as previously described [15]. The titres were 
displayed as the number of plaque-forming units (PFU) per ml or as 50% (median) ciliostatic dose 
(CD50) per mL. 
2.3. In Vivo Characterisation  
SPF RIR chickens were housed in raised floor pens held within separate positive-pressure 
HEPA-filtered rooms in groups of 20, 30, or 35 birds. The experimental design is detailed in Figure 1. 
Chickens were randomly assigned to one of six groups (Table 1), and the sex of the birds was not 
taken into consideration. Eight-day-old chicks were inoculated (classified as primary vaccination) 
with 104 PFU of BeauR-M41(S) or the equivalent dose (as determined by a standard curve comparing 
titre of infectious virus quantified by plaque assay or ciliostatic dose) of 3 log10 CD50 BeauR-4/91(S) 
in 0.1 ml phosphate buffered saline (PBS) which was split between conjunctival and intranasal routes. 
Mock vaccinated (control) chickens were inoculated via the same route with 0.1 ml PBS. Fourteen 
days after the primary vaccination (dppv), chickens received a second vaccination of BeauR-M41(S), 
BeauR-4/91(S), or PBS which was administered in the same dose and manner as the primary 
vaccination. Nine days post-secondary vaccination (dpsv), a challenge dose of 3 log10 CD50 QX or 
0.1 ml PBS was administered via the same route (Table 1). Birds were monitored for clinical signs 
including snicking, rales, watery eyes, and nasal discharge from 3–7 days after each inoculation with 
IBV, as previously described [44].  
On specific dppv and days post-challenge (dpc), five or 10 randomly selected chickens were 
culled by cervical dislocation (Table 1). A sample size of five birds was used for the mock control 
group at all time-points and all vaccinated groups at 4 dppv. This sample size of five birds and 10 
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tracheal rings per bird was calculated to detect a significant difference in mean ciliary activity of 25% 
(95% certainty, 80% power, two-sided) between groups post IBV infection [45]. To increase statistical 
power for the detection of differences in protection levels between vaccinated groups, the sample size 
was increased to 10 birds post-challenge. A panel of tissues was collected and stored in RNAlater 
(Ambion, Austin, Texas, United States) or PBS depending on the downstream analysis of viral RNA 
load and infectious viral load, respectively. Tissues collected included the following: Harderian 
gland, lower eyelid containing the conjunctiva-associated lymphoid tissue (CALT), and trachea. 
Blood samples were collected at specific time-points and clarified by low speed centrifugation at 700 
x g for 5 minutes to collect serum. 
2.4. Ciliary Activity Assay 
Tracheas were removed from five randomly selected chickens per group at 4 dppv and from five 
or 10 chickens per group at 4 dpc (Table 1). Ciliary activity was assessed as previously described 
[22,23]. Briefly, 10 one mm rings were cut from each trachea, three from the top, four from the middle, 
and three from the bottom. Each ring was assessed for ciliary activity and scored using the following 
system: 0 (no ciliated cells beating, complete ciliostasis), 25, 50, 75, and 100% of cilia beating. The 
average (mean) of 10 rings was calculated and presented as % ciliary activity. The assessor was 
blinded to the experimental group. A bird was considered to be protected if 50% or more ciliary 
activity was retained in nine of 10 tracheal rings; and this was needed in 80% of the group [46]. The 
remaining trachea was stored in RNA later or in PBS.  
2.5. Assessment of Infectious Virus in Tracheal Samples  
Tracheal rings used for the ciliary activity assay at 4 dppv and 4 dpc were homogenised in 500 
µl PBS using a Tissuelyser II (Qiagen, Hilden, Germany), producing tissue-derived supernatant that 
was subsequently clarified by low speed centrifugation. To determine whether infectious virus was 
present in the trachea at 4 dppv, 10-day-old SPF RIR embryonated hens’ eggs were inoculated with 
100 µL of tracheal tissue-derived supernatant. Allantoic fluid was harvested 48 hours post infection 
(hpi) and assessed for viral presence by RT-PCR using primers specific for the 3ʹ UTR, as previously 
described [44]. Tissue-derived supernatant from tracheas collected at 4 dpc was titrated in ex vivo 
TOCS as previously described [15]. The dose required to cause 50% ciliostasis (CD50) was calculated 
according to the Reed and Muench method [47]. 
2.6. Infectious Bronchitis Virus ELISA  
Serum samples collected pre-challenge, 7 dpsv, and at 4 and 14 dpc were assessed with a 
commercial IBV antibody test kit (BioChek BV, Reeuwijk, The Netherlands), coated with inactivated 
whole IBV antigen. The 7 dpsv sera were diluted to 1:80. For determining titre endpoints, the 4 and 
14 dpc sera were two-fold serially diluted in the range 1:80–1:2560, prior to incubation. After sample 
incubation, the remaining steps were followed directly according to the manufacturer’s instructions. 
The sample/positive (S/P) ratio was determined by the following equation: (Mean sample – Mean Kit 
Negative)/(Mean Kit positive – Mean Kit Negative). The S/P ratios above 0.2 were considered to be 
positive for IBV antibodies. Polyclonal chicken serum raised against IBV QX was included on each 
independent test plate as a reference control (kindly gifted by J.J. de Wit, GD Animal Health). 
2.7. Detection of Viral RNA 
Total RNA was isolated from Harderian gland and CALT using the RNeasy® Mini Kit and 
DNase-treated following the manufacturer’s instructions (Qiagen). cDNA was synthesised from 1 µg 
of tRNA using Superscript IV Reverse Transcriptase (Invitrogen by Life Technologies, Carlsbad, 
California, United States) with a random oligo primer as per the manufacturer’s instructions. For 
quantification of viral RNA load, qPCR was performed using the Taqman Universal PCR Master Mix 
(Applied Biosystems, Foster City, California, United States) with primers and probes specific to the 
5ʹ UTR region [48]. The RT-qPCR data was analysed in the same manner as previously described [12]. 
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2.8. Statistics 
Serum antibody levels, ciliary activity, infectious viral load, and viral RNA load were tested for 
normality. Differences between ciliary activities, and pre-challenge serum titres were evaluated by 
non-parametric Kruskal–Wallis adjusted post hoc for multiple comparisons, Mann–Whitney, and 
Dunn’s, respectively. Differences between post-challenge serum titres were assessed by two-way 
ANOVA, adjusted for post hoc analysis Tukey’s pairwise comparisons. The differences between the 
viral load RT-qPCR data and infectious viral load titres were statistically evaluated by the parametric 
one-way ANOVA test adjusted for post hoc analysis Tukey’s pairwise comparison. Differences in 
viral titres in response to serum neutralisation were evaluated using a two-way ANOVA with a 
Tukey test for multiple comparisons. Mean and standard error of the mean (SEM) values are 
displayed. 
3. Results 
3.1. Confirmation that the S Gene from a Pathogenic Strain Does Not Confer Virulence to a Non-Pathogenic 
Strain  
To elucidate whether homologous or heterologous vaccination, with rIBV expressing the S gene 
from either 4/91 or M41-CK, could cause any clinical signs post-vaccination and could induce cross-
protection against challenge with QX, a vaccination challenge experiment in SPF RIR chicks was 
conducted (Figure 1). Eight-day-old chicks were vaccinated with PBS, BeauR-4/91(S) or BeauR-
M41(S), as per the grouping in Table 1. Clinical signs were not observed post-vaccination (Figure 2a) 
and the infectious vaccine virus was not recovered from the trachea at four days post-primary 
vaccination (dppv) (data not shown). Tracheal ciliary activity at four dppv in BeauR-4/91(S) and 
BeauR-M41(S) infected birds was comparable with the mock-vaccinated birds; the group means were 
87%, 95%, and 87.5%, respectively (Figure 2b). These observations support previous reports that the 
S gene from a pathogenic isolate does not confer virulence to the apathogenic rIBV Beau-R [12,15,16].  
 
Figure 1. Schematic detailing protocol for the in vivo heterologous vaccine-challenge experiment. 
Groups of eight-day-old specific-pathogen-free (SPF) Rhode Island Red (RIR) chickens received a 
primary vaccination of BeauR-M41(S), BeauR-4/91(S), or phosphate buffered saline (PBS). Two weeks 
(14 days) later, birds received a second vaccination of either BeauR-M41(S), BeauR-4/91(S), or PBS. 
Nine days post-secondary vaccination (dpsv), birds were challenged with QX or mock challenged 
with PBS. Clinical signs were assessed for both post-vaccination and post-challenge birds. At defined 
intervals, randomly chosen birds were culled from each group and a variety of tissues harvested. 
Serum was collected pre-vaccination, post-vaccination (pre-challenge), and post-challenge. Tracheal 
ciliary activity was assessed at 4 days post-primary vaccination (dppv) and 4 days post-challenge 
(dpc). The experiment ended at 14 dpc with all remaining birds culled. 
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3.2. Chickens Vaccinated with BeauR-M41(S) or BeauR-4/91(S) Exhibited Reduced Clinical Signs in 
Response to QX Challenge  
Fourteen days following primary vaccination, each group received a second vaccination of either 
BeauR-M41(S), BeauR-4/91(S), or PBS (as described in Table 1). The vaccination scheme included both 
homologous and heterologous boosts and, as previous research has indicated, vaccination order 
could influence the level of protection induced [25,49,50]. There were no clinical signs observed post-
secondary vaccination (Figure 2c), further demonstrating the S gene from a pathogenic isolate cannot 
confer pathogenicity to a non-pathogenic strain. 
Nine dpsv, birds were challenged with QX or mock challenged with PBS. From two to seven 
dpc, all groups, except those in the mock vaccinated/mock challenged control group 
(Mock/Mock/Mock), exhibited snicking and rales (Figure 3a,b). Until 5 dpc, there were no differences 
in both snicking rates and rales between all vaccinated/challenged groups and the mock 
vaccinated/challenged group (Mock/Mock/QX) (Figure 3a,b). At 6 dpc, the rate of snicking in the 
group vaccinated with BeauR-M41(S)/BeauR-M41(S) and the mock vaccinated/challenged control 
group (Mock/Mock/QX) increased, whereas in all other vaccinated groups it began to decrease. With 
the peak snicking rate in the mock vaccinated/challenged control birds (Mock/Mock/QX), one snick 
per bird per min, occurring at seven dpc as compared with the vaccinated/challenged groups (except 
for BeauR-4/91(S)/BeauR-4/91(S)) which exhibited less than 0.25 snicks per bird per min at the same 
time-point. At 14 dpc, snicking rates were comparable between all groups, indicating that, at this 
point, those birds challenged with QX had clinically recovered from the infection. The area under the 
curve (AUC) analysis using the trapezium rule indicates that the rates of snicking in the vaccinated 
groups were similar with mean values ranging from 2.48 for birds vaccinated with BeauR-
4/91(S)/BeauR-M41(S) to 4.37 for birds vaccinated with BeauR-4/91(S)/BeauR-4/91(S). The mean AUC 
values of the snicking observed in the BeauR-M41(S)/BeauR-M41(S) and BeauR-M41(S)/BeauR-
4/91(S) vaccinated groups were 3.51 and 3.08, respectively. In contrast, the mean AUC value for the 
snicking of the mock vaccinated/challenged control (Mock/Mock/QX) group was 7.16, and it was 0.28 
for the mock vaccinated/mock challenged control group (Mock/Mock/Mock). The pattern of rales 
followed a similar trend, as vaccinated groups displayed lower percentages at six and seven dpc as 
compared with the mock vaccinated/challenged control (Mock/Mock/QX). Notably at seven dpc, 
rales were only observed in the mock vaccinated/challenged control group (Mock/Mock/QX) and, at 
six dpc, no rales were observed in birds vaccinated with BeauR-M41(S)/BeauR-M41(S) or BeauR-
4/91(S)/BeauR-M41(S). The AUC analysis of the rales observed in the vaccinated groups ranged from 
mean values of 69.6 in the BeauR-M41(S)/BeauR-M41(S) vaccinated group to 120.0 in the BeauR-
4/91(S)/BeauR-M41(S) vaccinated group. The rales observed in the BeauR-M41(S)/BeauR-4/91(S) and 
BeauR-4/91(S)/BeauR-4/91(S) groups had mean AUC values of 95.0 and 104.1, respectively, whilst the 
mock vaccinated/challenged control (Mock/Mock/QX) mean AUC value was considerably higher, at 
209.9. There were no rales observed in the mock vaccinated/mock challenged control group 
(Mock/Mock/Mock). It was not possible to calculate whether these differences in mean AUC values 
were statistically significant due to the method used for the data collection (with a single value per 
group for each day), however, it appeared that with respect to clinical signs of snicking and rales, all 
vaccination regimes allowed the birds to recover quicker from the QX challenge infection. 
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Table 1. Details of groups, vaccination schedule, sampling points, and bird numbers. 
Primary 
Vaccination 
No. of Birds 
Sampled 
Secondary 
Vaccination Challenge 
No. of Birds 
Sampled 
Total no. of 
Birds Per 
Group 
Mock 
5 birds on 
4 dppv 
Mock Mock 
5 birds on 
2, 4 and 14 
dpc 
20 
BeauR-M41(S) 
5 birds on 
4 dppv 
BeauR-M41(S) QX 
10 birds on  
2 and 4 dpc; 
9 * birds on 
14 dpc  
35 
BeauR-4/91(S) 
5 birds on 
4 dppv 
BeauR-4/91(S) QX 
10 birds on 
2 and 4 dpc; 
9 birds on 14 
dpc 
34 # 
BeauR-M41(S) 0 BeauR-4/91(S) QX 
10 birds on 
2, 4 and 14 
dpc 
30 
BeauR-4/91(S) 0 BeauR-M41(S) QX 
10 birds on  
2, 4 and 14 
dpc  
30 
Mock 0 Mock QX 
10 birds on 
2 and 4 dpc; 
12 birds on 14 
dpc 
32 
Abbreviations: dppv, days post-primary vaccination; dpc, days post-challenge. *, one bird died 
unexpectedly post-vaccination and the cause of death was not related to infectious bronchitis virus 
(IBV); #, one bird died before the study started and the cause of death was not related to IBV. 
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Figure 2. The S gene from a pathogenic strain does not confer virulence to a non-pathogenic strain. 
SPF birds, at eight days of age, were vaccinated with either BeauR-M41(S), BeauR-4/91(S), or PBS for 
mock vaccination. (a) The number of snicks in each group was assessed from day three to seven days 
post-primary vaccination (dppv). The numbers of snicks were independently counted over a two-
minute period by two or three persons with the average (mean) of these scores presented; (b) Trachea 
was harvested from five randomly sampled birds four dppv. Each trachea was sectioned in 10 × 1 mm 
rings and the ciliary activity of each ring was assessed by light microscopy and the percentage activity 
calculated. Plotted points represent individual birds and the mean activity of the 10 rings assessed. 
Error bars represent standard error of the mean (SEM). Statistical differences were evaluated using a 
Kruskal–Wallis test followed by a post hoc Mann–Whitney test corrected for multiple comparisons; 
no differences were identified; (c) Fourteen days post-primary vaccination, birds received a secondary 
vaccination of either BeauR-M41(S), BeauR-4/91(S), or PBS for mock vaccination. The numbers of 
snicks in each group were independently counted over a two-minute period by two or three persons 
from day three to seven post-secondary vaccination (dpsv) with the average (mean) of these scores 
presented. Snicking post-secondary vaccination was comparable between the vaccinated groups and 
the mock vaccinated groups. 
3.3. Vaccination with BeauR-M41(S) or BeauR-4/91(S) Failed to Protect against Tracheal Ciliostasis Induced 
by a QX Heterologous Challenge 
Tracheal ciliary activity was assessed in tracheas harvested at four dpc from ten randomly 
selected chickens per group except for the mock vaccinated/mock challenged group 
(Mock/Mock/Mock) in which five birds were assessed (Figure 3c). The industry standard for the 
assessment of IBV vaccines, set by the European Pharmacopeia, states that for a chicken to be 
classified as protected, at least 50% ciliary activity must be retained post-challenge in nine out of 10 
tracheal rings [46]. The mean ciliary activity for the vaccinated groups ranged from 2.25%–18.75% 
(Table 2). Mock vaccinated/challenged control (Mock/Mock/QX) and the mock vaccinated/mock 
challenged control groups (Mock/Mock/Mock) exhibited 1% and 80.5% ciliary activity, respectively. 
Although there were some variations in the ciliary activity of the mock vaccinated/mock challenged 
control group such that only one bird had >90% ciliary activity, this did not alter the interpretation 
of vaccine effectiveness. Ciliary activity in the mock vaccinated/challenged group (Mock/Mock/QX) 
and the vaccinated groups, except BeauR-4/91(S)/BeauR-4/91(S), were significantly lower as 
compared with the mock vaccinated/mock challenged control (Mock/Mock/Mock) (p < 0.05). 
Interestingly, two birds within the BeauR-4/91/BeauR-4/91 vaccinated group retained ciliary activity 
comparable to mock vaccinated/mock challenged birds (Mock/Mock/Mock). One of these birds was 
classified as fully protected with 10 of 10 rings assessed retaining 90% or more ciliary activity (Table 
2). The second bird retained this level of ciliary activity in seven of 10 rings assessed.  
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Figure 3. Vaccination with BeauR-M41(S) or BeauR-4/91(S) reduced the clinical signs observed after 
challenge with QX but was not able to protect against tracheal ciliostasis. Nine days post-secondary 
vaccination, birds were challenged with QX or mock challenged with PBS. (a) The numbers of snicks 
in each group were assessed from 2 to 7 dpc. Snicks were independently counted by two or three 
persons over a two-minute period with the average of these scores presented; (b) Birds were 
individually assessed for tracheal rales from 2 to 7 dpc. The percentage of birds per group positive 
for rales was calculated; (c) Trachea was harvested from 5 or 10 randomly sampled birds at 4 dpc. 
Each trachea was sectioned in 10 × 1 mm rings and the ciliary activity of each ring was assessed by 
light microscopy and the percentage activity calculated. Plotted points represent individual birds and 
the mean activity of the 10 rings assessed. Error bars represent SEM. Statistical differences were 
evaluated using a Kruskal–Wallis test followed by a post Hoc Mann–Whitney test corrected for 
multiple comparisons and are highlighted by * (p < 0.0001). Ciliary activity in all groups except BeauR-
M41(S)/BeauR-4/91(S) was significantly reduced as compared with the mock vaccinated/mock 
challenged (Mock/Mock/Mock) group; ciliary activity in all vaccinated groups was comparable to the 
mock vaccinated/challenged (Mock/Mock/QX) control group. 
  
Vaccines 2020, 8, 330 10 of 19 
 
Table 2. Assessment of protection against ciliostasis associated with BeauR-M41(S) and BeauR-4/91(S) 
vaccination following challenge with QX. 
Primary Vaccination/ 
Secondary Vaccination/ 
Challenge 
% Ciliary 
Activity (Mean 
± SD) 
No. of Birds with 90% Ciliary 
Activity/Total No. of Birds 
Examined 
% of Group 
Protected 
Mock/Mock/Mock 80.50 ± 11.65 1/5 N/A 
BeauR/M41(S)/BeauR-
M41(S)/QX 5.75 ± 3.13 0/10 0 
BeauR-4/91(S)/BeauR-
4/91(S)/QX 18.75 ± 34.73 1/10 10 
BeauR-M41(S)/BeauR-
4/91(S)/QX 
6.25 ± 10.22 0/10 0 
BeauR-4/91(S)/BeauR-
M41(S)/QX 2.25 ± 4.78 0/10 0 
Mock/Mock/QX 1.00 ± 3.16 0/10 0 
3.4. Vaccination with a Heterologous Spike Protein Resulted in Reduced Viral Load in Homologous Boosted 
Vaccinated Groups after QX Challenge 
To assess the implications of the vaccine combinations on infectious viral load, tissue-derived 
supernatant, prepared from tracheal rings harvested at four dpc, were titrated in ex vivo TOCs 
(Figure 4). There were no infectious virus isolated from tracheas harvested from the mock 
vaccinated/mock challenged birds (Mock/Mock/Mock). The tracheal viral loads were significantly 
lower (p < 0.05) in the two groups that received homologous primary and secondary vaccinations, 
i.e., BeauR-M41(S)/BeauR-M41(S) and BeauR-4/91(S)/BeauR-4/91(S) as compared with the mock 
vaccinated/challenged control group (Mock/Mock/QX). The tracheal viral loads of birds inoculated 
with heterologous primary and secondary vaccinations, BeauR-M41(S)/BeauR-4/91(S) and BeauR-
4/91(S)/BeauR-M41(S), were comparable to the mock-vaccinated/challenged control group 
(Mock/Mock/QX). Interestingly, two birds from the BeauR-4/91(S)/BeauR-4/91(S) vaccinated group 
with post-challenge ciliary activity that was comparable with the mock controls, also had a 
comparable tracheal viral load with the group average (mean) (3.5, 3.8, and 3.13 log10 CD50/ml, 
respectively), and with the mock vaccinated/challenged control group (Mock/Mock/QX), at 4.06 log10 
CD50/ml. Therefore, this observation could indicate that infectious viral load and ciliary activity, 
therefore, do not always necessarily correlate.  
 
Figure 4. Vaccination with BeauR-M41(S)/BeauR-M41(S) and BeauR-4/91(S)/BeauR-4/91(S) resulted 
in a reduction in infectious viral load in response to the QX challenge within the trachea 4 dpc. Tissue-
derived supernatant prepared from tracheas harvested at 4 dpc were titrated in ex vivo tracheal organ 
cultures (TOCs). Data points represent individual birds, with lines representing the mean and 
standard deviation (SD). Statistical differences between vaccinated groups and mock 
vaccinated/challenged control group (Mock/Mock/QX) highlighted by * (p < 0.05) were evaluated 
using a one–way ANOVA with a Tukey test for multiple comparisons. 
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Viral RNA loads in the head-associated lymphoid tissues at two and four dpc were determined 
by RT-qPCR (Figure 5). At two dpc (Figure 5a,b), there were no significant differences identified 
between the vaccinated/challenged groups and mock vaccinated/challenged control group 
(Mock/Mock/QX). At four dpc in the CALT, but not in the Harderian gland (Figure 5c,d), a significant 
reduction in viral RNA load was detected in the groups which received different primary and 
secondary vaccinations, i.e., BeauR-M41(S)/BeauR-4/91(S) and BeauR-4/91(S)/BeauR-M41(S) (p < 
0.05). However, there was no significant reduction in viral load in groups which received the same 
primary and secondary vaccination, i.e., BeauR-M41(S)/BeauR-M41(S) and BeauR-4/91(S)/BeauR-
4/91(S), both of which had lower infectious viral load in the trachea (Figure 4).  
 
Figure 5. Vaccination with BeauR/M41(S)/BeauR-4/91(S) and BeauR-4/91(S)/BeauR-M41(S) resulted 
in a reduction in viral load in response to a QX challenge in the conjunctiva-associated lymphoid 
tissue (CALT) at 4 dpc. Relative viral RNA loads (expressed as corrected 40 cycle threshold) were 
assessed at specific time-points post-challenge. (a) Harderian gland at 2 dpc; (b) CALT at 2 dpc; (c) 
Harderian gland at 4 dpc; (d) CALT at 4 dpc. Data points are shown as the mean of three technical 
replicates per individual bird. Lines represent group mean and SEM. Statistical differences between 
the groups were evaluated using a one-way ANOVA with a TUKEY test for multiple comparisons. 
Significant differences between vaccinated groups and the mock vaccinated/challenged control group 
(Mock/Mock/QX) are highlighted by * (p < 0.05). 
3.5. Vaccination with rIBV Induced the Production of IBV-Specific Antibodies and Primed Chickens for a 
Boosted Humoral Response to Challenge 
Serum IBV-specific antibodies were assessed post-vaccination, at seven dpsv, and post-
challenge, at four and 14 dpc, and compared with the mock vaccinated/challenged (Mock/Mock/QX) 
control (Figure 6). At seven dpsv (pre-challenge), mean anti-IBV titres were significantly higher in all 
the vaccinated groups as compared with the mock vaccinated/mock challenged (Mock/Mock/Mock) 
control (p < 0.0001, Figure 6a), demonstrating the vaccination regimes employed had induced IBV-
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specific serum antibodies. However, there were no significant differences across the vaccinated 
groups pre-challenge. At four dpc, serum titres were significantly higher in the vaccinated groups as 
compared with the mock vaccinated/challenged control group (Mock/Mock/QX) (Figure 6b, p < 0.05), 
indicating that the rIBV vaccination primed the birds for challenge and induced strong humoral 
response, as shown previously [12]. Interestingly, there were significant differences in the capability 
of the rIBV vaccines expressing different S proteins to induce IBV specific responses. The highest 
titres were induced by a heterologous vaccination with BeauR-4/91(S) followed by BeauR-M41(S). 
When the birds were vaccinated in the reverse order, i.e., BeauR-M41(S)/BeauR-4/91(S), the titres 
were significantly lower (p < 0.0001). Vaccination with BeauR-M41(S)/BeauR-4/91(S) or with BeauR-
4/91(S)/BeauR-4/91(S) induced similar titres, whereas vaccination with BeauR-M41(S)/BeauR-M41(S) 
induced the lowest titres (Figure 6b). Collectively, this indicates that the order of vaccination can 
impact the magnitude of humoral responses induced to rIBV. Serum titres in the mock 
vaccinated/challenged (Mock/Mock/QX) control group remained below detection level. At 14 dpc, 
serum antibody titres were still significantly higher in all vaccinated groups as compared with the 
mock vaccinated/challenged (Mock/Mock/QX) control group (Figure 6c, p < 0.0001), providing 
evidence of a boosted antibody response in vaccinated groups in response to the challenge with a 
heterologous strain, QX. At 14 dpc, there were no significant differences between the anti-IBV titres 
in the vaccinated groups (Figure 6c). 
 
Figure 6. Vaccination with recombinant infectious bronchitis virus (rIBV) BeauR-M41(S) and BeauR-
4/91(S) induced the production of IBV-specific antibodies and primed chickens for a boosted humoral 
response to challenge. Serum anti-IBV antibody titres were assessed by commercial ELISA (BioCheck, 
Reeuwijk, The Netherlands). (a) Pre-challenge serum samples were diluted 1:80 and dilutions 1:80 
through to 1:2560 were investigated for (b) 4 dpc serum samples and (c) 14 dpc serum samples. The 
mean S/P of four technical replicates of each bird from each group is presented. The cut-off threshold 
for positive samples is S/P ratio = 0.2. The error bars represent SD. Statistical differences between the 
group antibody titre means at (a) pre-challenge were assessed using Kruskal–Wallis and Dunn’s 
multiple comparison test. Post-challenge (b) and (c), antibody titres were assessed using a one-way 
ANOVA with a Friedman test and Dunn’s multiple comparison test. Significant differences between 
vaccinated groups and the mock vaccinated/challenged (Mock/Mock/QX) control group are 
highlighted by * (p < 0.05), ** (p < 0.01), and **** (p < 0.0001). 
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4. Discussion 
In this study, vaccination with BeauR-M41(S) or with BeauR-4/91(S) in either homologous or 
heterologous booster regimes, did not induce a fully protective immune response against the 
heterologous QX challenge as defined by the European Pharmacopeia as protection against ciliostasis 
[46]. Ciliary activity in all vaccinated groups post-challenge was reduced to less than 25% (Figure 3). 
Interestingly, two birds that were vaccinated with BeauR-4/91(S)/BeauR-491(S) were observed to 
retain ciliary activity post-challenge, however, only one bird could be deemed to be protected in 
accordance with European Pharmacopeia [46] standards (Table 2). However, despite the overall 
reductions in ciliary activities observed in all the vaccinated groups, there were indications that each 
of the vaccination strategies induced an immune response that resulted in positive differences post-
challenge. All vaccinated groups appeared to recover more rapidly from clinical signs than the mock 
vaccinated/challenged (Mock/Mock/QX) control group (Figure 3). The homologous vaccinated 
groups, BeauR-M41(S)/BeauR-M41(S) and BeauR-4/91(S)/BeauR-4/91(S), were the only groups that 
had reduced infectious tracheal viral load, at four dpc as compared with the mock 
vaccinated/challenged (Mock/Mock/QX) group (Figure 4). The heterologous primary and secondary 
vaccination, BeauR-M41(S)/BeauR-4/91(S) or BeauR-4/91(S)/BeauR-M41(S), was associated with 
lower viral RNA loads in the CALT, at four dpc as compared with the mock vaccinated/challenged 
(Mock/Mock/QX) control group. In addition, all vaccinated groups at seven dpsv and four dpc had 
higher titres of serum anti-IBV antibody than the mock vaccinated/challenged (Mock/Mock/QX) 
control group, demonstrating that the vaccination had induced a humoral response (Figure 6). 
Unfortunately, whether these humoral responses included neutralising antibody toward QX remains 
an unanswered question due to the inability to propagate the QX strain used in this study in vitro 
[14].  
Numerous studies have addressed the question of cross-protective immunity against IBV and 
have reported varying degrees of success [21,22,24,25,49,51]. The S glycoprotein is the main inducer 
of protective immunity [8,9,52]. It is thought that the chances of a successful vaccination decrease as 
the amino acid homology between the S glycoprotein of the vaccine and challenge strain also 
decreases [22,49]. As homology decreases, the likelihood of differences arising in important 
neutralising epitopes increases. It is possible, however, for vaccines to offer successful protection 
against heterologous challenge when sequence homology between the vaccine and challenge strain 
is deemed to be low (as reviewed in [26]), presumably due to conserved structural homology of 
epitopes involved in viral neutralisation. A small number of virus neutralising epitopes are likely to 
play a disproportionate role in cross-protection [22]. Although the locations of some neutralising 
monoclonal antibody epitopes have been identified [53–55], it remains unknown which epitopes are 
required for the successful induction of cross-protective immunity. Therefore, it continues to be 
important to investigate and assess the level of protection afforded by vaccine strategies against 
heterologous challenge. 
Several previous studies have investigated cross-protective immunity utilising commercial 
vaccines produced via the traditional method of passaging a field isolate through embryonated hens’ 
eggs to produce an attenuated virus [21,25,49,50]. As such, these commercial vaccines closely 
resemble the challenge strains, and therefore it is difficult to assess the individual contribution of 
each viral protein towards both homologous and heterologous immunity. The recombinant viruses 
used in this study, also used by Hodgson et al. (2004), Armesto et al. (2011), and Ellis et al. (2018), 
express heterologous S glycoproteins from a rIBV vector [12,15,16]. As the other proteins in the 
vaccine viruses are Beaudette derived, the utilisation of BeauR-M41(S) and BeauR-4/91(S) vaccines 
allowed for characterisation of the specific role of the 4/91 and M41-CK S glycoproteins in induction 
of a protective immune response against a heterologous QX challenge. Amino acid sequence identity 
among E, M, and N of QX and Beau-R is relatively low at 88%, 92%, and 90%, respectively, and 
additionally, the Beaudette strain is considered to be a weak stimulator of humoral immune 
responses in vivo [15,56]. In previous studies that have investigated vaccination with both 
Massachusetts and 4/91 serotypes against a QX challenge, it has been difficult to ascertain whether 
the protective response induced is solely the result of the presence of the S glycoprotein of either the 
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Massachusetts strain or 4/91 strain [21,26,50]. In this study, we used rIBVs to address the role of the 
spike glycoprotein in cross-protection, along with an analysis of whether the order of heterologous 
vaccination impacted cross-protection. 
The order in which live attenuated IBV vaccines are administered has been shown to affect the 
outcome of heterologous challenge. Cook et al. (1999) concluded that better cross-protection was seen 
when a Massachusetts serotype vaccine, Ma5, was administered before a 4/91 vaccine [49]. 
Additionally, Awad et al. (2016) and Bru et al. (2017) demonstrated a degree of cross-protection using 
a Massachusetts vaccine followed by a secondary vaccine of a different serotype, however, the reverse 
order was not directly compared [25,50]. Whilst in terms of ciliary activity, there was no difference 
between those birds vaccinated with BeauR-M41(S)/BeauR-4/91(S) and BeauR-4/91(S)/BeauR-M41(S) 
in this study, the order in which the BeauR-M41(S) (Massachusetts serotype) and BeauR-4/91(S) (4/91 
serotype) were administered did appear to have affected serum antibody levels. Serum antibody 
titres assessed at four dpc were significantly higher in the group vaccinated with BeauR-
4/91(S)/BeauR-M41(S) as compared with the other vaccination regimes, suggesting, in this study, that 
a 4/91 vaccine followed by a Massachusetts vaccine could have enhanced the level of seropositivity.  
Despite the indication that the vaccination strategies employed in this study induced an immune 
response, ultimately the vaccines did not offer protection against ciliostasis following a QX challenge, 
which is the gold standard method of assessing protection. This was unexpected as it contradicts 
previous work that has demonstrated that commercially available Massachusetts and 4/91 vaccines 
confer protection against a heterologous QX challenge [21,50,57]. Awad et al. (2016) investigated 
combinations of Ma5 or H120, both of the Massachusetts serotype, alongside 793B vaccines (4/91 
serotype) against heterologous QX challenge; ciliary activity was reported at 68% and 92%, 
respectively [50]. Similarly, de Wit et al. (2011) used a combination of Massachusetts vaccines or a 
mixture of Massachusetts combined with a D274 serotype, followed by a 793B vaccine and reported 
protection, as defined by ciliary activities of 51% and 89%, respectively [26]. Terregino et al. (2008) 
also evaluated a vaccination with Ma5 and 4/91, against a QX challenge [21]. Unlike this study in 
which challenge virus was detected in tracheas from all vaccinated/challenged chickens, Terregino et 
al. (2008) isolated no virus post-challenge in vaccinated SPF chickens. However, it is difficult to make 
direct comparisons between vaccine-challenge experiments due to differences in the range of 
parameters which include age, breed, SPF status, and the basis for defining protection (ciliary activity, 
viral load or seropositivity) (reviewed by [58,59]). Terregino et al. (2008) did not assess ciliary activity 
and it has been well documented that viral load and ciliary activity do not always correlate 
[12,15,16,58]. Similarly, seropositivity and protection do not always correlate (reviewed by [58]). A 
recent study into correlates of IBV-vaccine-induced protection revealed that birds with the highest 
monocyte major histocompatibility complex (MHC) II expression had the weakest vaccine-induced 
protection [60]. Whilst de Wit et al. (2011) assessed ciliary activity at 5, 8, and 11 dpc, these sampling 
time-points were not directly comparable to the time-point, four dpc, used here [26]. In addition, 
there were no clinical signs data reported, and the age of the chickens, at both vaccination and 
challenge, were also not comparable. It is also worth noting that the vaccinated birds in both studies 
by both Terregino et al. (2008) and Awad et al. (2016), were vaccinated in the presence of maternally-
derived antibody, although this is thought to have a negative impact on vaccination [61]. The inability 
of BeauR-M41(S) and BeauR-4/91(S) to induce a protective immune response against heterologous 
virus challenge, in terms of both ciliary activity (Figure 2c) and challenge virus replication (Figure 2) 
is a notably different result to that published by [21,50,57]. This raises some interesting questions and 
could indicate that the S glycoprotein from either M41-CK and/or 4/91 alone expressed by a Beaudette 
backbone may not be sufficient to elicit an adequately protective immune response against a 
heterologous QX challenge. 
The other possibility is the limited replication of the vaccine viruses in vivo, since as observed 
in previous studies [12,15,16], neither rIBV BeauR-M41(S) nor BeauR-4/91(S) could be detected in the 
trachea post-vaccination (data not shown). The rIBV Beau-R, the genetic backbone of the vaccine 
viruses used here, is a molecular clone of the apathogenic Beaudette-CK strain [38]. Ellis et al. (2018) 
investigated the ability of Beau-R expressing heterologous S1 or S2 subunits to induce protective 
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immune responses against homologous challenge [12]. Whilst rIBV BeauR-M41(S) induced partial 
protective immunity, as also reported by Hodgson et al. (2004) [15], the response was not robust. In 
addition, ciliary activity, post-challenge (65%), fell short of the European Pharmacopeia standards for 
full protection, a finding comparable with both Hodgson et al. (2004) [15], and Armesto et al. (2011) 
who investigated homologous and heterologous challenge using BeauR-4/91(S) [16]. It has long been 
established that the Beaudette strain cannot establish a long-lasting productive infection in vivo, with 
the molecular clone Beau-R behaving similarly [15,56]. Interestingly, chickens inoculated with 
Beaudette do produce virus neutralising antibodies, however, these rapidly decrease over time [56], 
presumably due to the lack of viral replication. 
5. Conclusions 
In summary, this study demonstrates that vaccination with rIBV BeauR-M41(S) and BeauR-
4/91(S) can induce anti-IBV humoral responses, however, these responses have not translated into 
protection against ciliostasis following a heterologous challenge. The inability of the rIBV vaccines to 
elicit a stronger protective immune response has raised several questions that are critical to answer 
to enable the design of the next generation of rationally attenuated vaccines. It is important to 
establish whether a less attenuated IBV vaccine backbone, with improved replication in vivo, would 
induce a protective immune response to both homologous and heterologous challenges, meeting the 
criteria defined by the European Pharmacopeia [46]. Additionally, it is relevant to explore whether 
replacement of other structural proteins (E, M, or N) in the rIBV Beau-R backbone, with those derived 
from pathogenic strains, improves the induction of an effective cross-protective immune response. 
Further work is required to identify the immunogenic epitopes presented on the S glycoproteins from 
different IBV serotypes to elucidate whether rationally designed vaccines expressing both cross-
reactive epitopes and serotype-specific epitopes are capable of inducing cross-neutralising 
antibodies, resulting in the generation of novel cross-protective IBV vaccines.  
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